Data Safety Monitoring Board Guidance To Provide Rules For Halting Trials
This article was originally published in The Gray Sheet
Executive Summary
FDA's draft guidance on data safety monitoring boards (DSMBs) will address when clinical trials should be stopped for safety or efficacy reasons.
You may also be interested in...
Risk-Based Approach To Clinical AE Reporting Needed – Medtronic’s Westrum
Clinical trial sponsors are limited in their ability to facilitate compliance with institutional review boards, even though investigators often lack thorough grounding in IRB policies, according to Medtronic Director of Clinical Affairs Barbara Westrum
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.